Biocon Ltd said on Tuesday that it agreed to buy a 7.7 per cent stake in its research services business from a unit of GE Capital for Rs 215 crore ($35.48 million).
Biocon said it would buy the stake in unit Syngene, which is involved in pharmaceutical contract research and manufacturing, from GE Equity International Mauritius.
Biocon had previously said it planned to take Syngene public, but has not given a timeline.